HONG KONG – A series of enquiries in Australia into tax payments by multinational pharmaceutical companies is likely to have little impact on their operations, particularly outside the country, despite the concern of authorities there.
NEW DELHI – A new report to the government of India suggests the adoption of a slew of measures to help domestic pharma firms, especially small firms that form the bulk of the industry, better understand the global regulatory landscape and meet compliance standards in advanced countries.
HONG KONG – Chinese researchers have discovered a novel nonasaccharide molecule – a nine-unit sugar chain – with potent anticoagulant activity that could avoid adverse effects, paving the way for the development of better treatments for thromboembolic diseases, they reported in the June 22, 2015, early online issue of Proceedings of the National Academy of Sciences.
SHANGHAI – Hangzhou-based Ascletis Inc. is aiming for a home turf advantage with its interferon-free regimen for chronic hepatitis C, having submitted investigational new drug applications to both the Mainland Chinese and Taiwanese Food and Drug Administrations.
NEW DELHI – India has launched a pharmaceutical price databank to be managed and operated by its drug pricing regulator, the National Pharmaceutical Pricing Authority (NPPA), to help consumers make informed product formulation and rate choices.
HONG KONG – An extract of a mushroom used in traditional Chinese medicine (TCM) reduces obesity in mice by altering the composition of the gut microbiota, suggesting it may prove useful for treating obesity and associated disorders in humans, according to a Taiwan study reported in the June 23, 2015, edition of Nature Communications.
SHANGHAI – Shanghai's Cellular Biomedicine Group Inc. (CBMG) has added a cancer vaccine to its pipeline, a Gvax vaccine it intends to combine with a PD-1 drug in a U.S. phase II study for non-small-cell lung cancer (NSCLC).
SHANGHAI – Beigene Co. Ltd. is betting its Bruton's tyrosine kinase inhibitor, BGB-3111, has world-class potential and is gearing up for proof-of-concept trials in the U.S. to find out. The company just received approval for its investigational new drug application from the FDA and is beginning to build up its U.S.-based operation to support the upcoming trials.
RSS